Innoviva
Drug Discovery and Development, Treatment Of Chronic Obstructive Pulmonary Disease
Drug Discovery and Development, Treatment Of Chronic Obstructive Pulmonary Disease
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a long-acting beta2 agonist (LABA), vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate (FF); ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA and LABA.
We have 9 contacts in our database, out of which 56% are decision makers. The distribution of leads are as follows:
In October, 2019 inva.com's total website visitor was 5409, None. Some key metrics are Average time spent on site is 0 minutes, Bounce Rate is 0% and average page per visit is 2 respectively.
We Verified inva.com server for email deliverability.
Microsoft today declared that it has acquired Affirmed Networks, an organization that specializes...
Perficient acquires Catalyst Networks, a Georgia corporation doing business as Brainjocks, which ...
Cognizant enters into an agreement to acquire the U.S.-based digital marketing consultancy Lev fo...
Masimo has agreed to acquire Germany-based TNI Medical AG for an undisclosed sum.
© Copyright 2014-2020 by GetCompanyInfo.com. All Rights Reserved.
